Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma

Ähnliche Einträge

• A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma
  von: Tetsu Tomonari, et al.
  Veröffentlicht: (2025)
• Antitumor effects and immune‐mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma
  von: Takanori Ito, et al.
  Veröffentlicht: (2024)
• Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
  von: Tetsu Tomonari, et al.
  Veröffentlicht: (2024)
• Effective Promotion of Proline‐Catalyzed Aldol Reaction in Water by Bile Acid Salt Surfactants
  von: Venanzio Raglione, et al.
  Veröffentlicht: (2024)
• Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage‐associated molecular pattern analysis
  von: Tomomi Ozaki, et al.
  Veröffentlicht: (2024)